Under the proposed legislation, insurance plans must either set the copayments, deductibles or coinsurance amounts for oral ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...

Drug resistance continues to limit the long-term benefit of many targeted therapies and chemotherapies against cancer. While “classical” small-molecule ...

Chemotherapy causes harsh side effects because it targets fast-growing cancer cells along with healthy cells like hair follicles, gut lining, and bone marrow. This leads to fatigue, nausea, hair loss, ...

Researchers shrink gastrointestinal tumors in mice using a yeast probiotic to deliver immunotherapy to the gut, offering a potentially novel strategy to target hard-to-reach gut cancers. Immunotherapy ...

Overcoming tumor resistance to chemotherapy drugs has long been a challenge for oncology clinicians and researchers. Now, a new study suggests that blocking a key protein, p300, may force damaged ...

Complete DPD deficiency markedly impairs 5-FU catabolism, increasing risk of early severe diarrhea, mucositis, neutropenia, ...

India, Feb. 10 -- In a special enforcement drive against spurious and substandard anticancer drugs, the Delhi Government ...

Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients' quality of life.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma ...